THE US Food and Drug
Administration has initiated a safety
review of the type 2 diabetes drug
pioglitazone (Actos).
The review comes on the back
of concerns raised after an
oservational study found that longterm
patients on high doses of
pioglitazone had an increased risk
of developing bladder cancer.
At present the FDA is
recommending health practitioners
continue to follow the label
directions when prescribing the drug.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 10
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.